“We are pleased to collaborate with Sobi, whose deep commitment to rare diseases aligns strongly with our mission,” says Johan Juhlin, CEO and Co-founder of Mavatar.  “Through advanced analytics of public transcriptomic data, we aim to contribute to a clearer understanding of IFNγ-driven mechanisms across relevant biological contexts.”

The underlying biology of rare and immune-mediated conditions

The project will investigate IFNγ-related molecular patterns across selected datasets, supporting broader scientific exploration in immune-mediated and rare disease research.

“Understanding the underlying biology of rare and immune-mediated conditions is essential for advancing research in the field,” says Emmanuel Monet, Head Medical Science Strategy,  Sobi. “Through this collaboration, we aim to further strengthen our scientific knowledge base using structured, data-driven analyses.”